Drug Profile
BGC 201259
Alternative Names: BGC 20-1259; RS 1259Latest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator BTG
- Developer BTG; SAFC Pharma
- Class Antidementias
- Mechanism of Action Acetylcholinesterase inhibitors; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 02 Apr 2009 Discontinued - Phase-I for Alzheimer's disease in Sweden (PO)
- 02 Apr 2009 Discontinued - Phase-I for Alzheimer's disease in United Kingdom (PO)